# Text Description automatically generated with medium confidence

|  |
| --- |
| **CLINICAL GUIDELINE** |
|  |
| BASHH Guideline on the Management of Balanoposthitis (and related penile skin conditions) 2025 Sarah K Edwards1, Pareswaran Shashidharan 2, Imali Fernanado 3, Georgina Morris 4  DayanVijeratnum 5, Jason Eng Kiat Lim6, Deepa Grover7 |
| 1.Consultant GU Physician, Bury St Edmunds, Cambridgeshire Community Services NHS Trust  2. Parmeswaran Sashidharan, Associate Specialist, Homerton Sexual Health Services, Homerton University Hospital  3. Imali Fernando, Consultant in Genitourinary Medicine, Honorary Clinical Senior Lecturer, University of Edinburgh  4. Georgina Morris, Consultant in Genitourinary Medicine and Lead Clinician, Salisbury NHS Foundation Trust Salisbury  5.Dayan Vijeratnam, Consultant Genito-urinary & HIV Physician Sexual Health Services Aldershot Centre for Health, Solent NHS Trust  6. Jason Eng Kiat Lim, Registrar in Genitourinary Medicine, HIV and Internal Medicine, Yuno Sexual Health, University Hospitals Bristol, and Weston NHS Foundation Trust  7.Deepa Grover, Clinical Effectiveness Group EditorClinical Effectiveness Group (CEG)  British Association for Sexual Health and HIV (BASHH) |
|  |
| **Short Title:** BASHH Balanoposthitis guideline |
| **Lead author(s):** Sarah Edwards |
| **Version No.:** 04 |
| **Version Date:** August 2025 |

[1. TITLE PAGE 1](#_Toc168562442)

2 WHAT IS NEW IN THE 2025 guideline

[3](#_Toc168562445) INTRODUCTION AND METHODOLOGY

4. AEITIOLOGY

[5](#_Toc168562446) gENERAL MANAGEMENT

[6](#_Toc168562447) INFECTIVE CAUSES

6.1 Candidal balanitis

6.2 Anaerobic infections

6.3 Aerobic infections

7.Balanoposthitis relating to STIs

7.1.Chlamydia

7.2Lymphogranuloma Venerum (LGV)

7.3Gonorrhoea

7.4 Syphilis

7.5 Chancroid

7.6 Granuloma Inguinale

7.7 Herpes Simplex Virus (HSV)

7.8 Huma Papilloma Virus (HPV)

7.9 Human Immunodeficiency Virus (HIV)

Trichomonas

Scabies

8. DERMATOlOGICAL PRESENTATIONS

8.1 Lichen sclerosus

8.2 Lichen Planus

8.3 Zoons /Plasma cell balanitis

8.4 Psoriasis and Circinate balanitis

8.5 Fixed Drug eruption

8.6 Penile intraepithelial neoplasia (PEIN)

9.Balanitis associated with Systemic disease

9.1 Sarcoid

9.2 Chrohn’s disease

9.3 Tuberculosis

9.4 Behçet’s Syndrome

APPENDIX 1

Fig 1 Flow diagram for Dermatological presentations

ACKNOWLEGDMENTS

**What is new in the 2025 guideline**

* Guideline reviewed to cover the diagnosis and management of infective causes of balanoposthitis and the recognition of other presentations, with initial treatment advice and reference to other relevant guidelines for management.

**Introduction and Methodology**

Objectives: The main objective is to aid recognition of the signs and symptoms and complications of penile skin conditions which may present in Sexual Health clinic attendees. This guideline concentrates on a selected group of conditions, which may present to sexual health services, either alone or in conjunction with other specialists. It is not intended as a comprehensive review of the treatment of all balanitis. The guideline is aimed primarily at people aged 16 years or older presenting to health care professionals working in sexual health services. The recommendations are primarily aimed at services offering level 3 care in sexually transmitted infections (STIs) management within the United Kingdom. However, the principles will apply to those presenting to level 1 and 2 services, and appropriate local referral pathways will need to be developed. This guideline offers recommendations on the diagnostic tests and treatment regimens needed for the effective management of infective balanoposthitis and includes the following conditions:

* Candidal balanoposthitis
* Anaerobic infection
* Aerobic infection
* Balanoposthitis relating to STIs

It also provides guidance on the recognition of the following causes of balanoposthitis and gives general management advice only but provides references to the appropriate guidelines for specialist referral and care:

* + Lichen sclerosus
  + Lichen planus
  + Zoon’s (plasma cell) balanitis
  + Psoriasis and circinate balanitis
  + Fixed drug eruptions
  + Penile intraepithelial neoplasia (PeIN)
  + Eczema
    - Seborrheic
    - Irritant / Allergic
  + Balanitis associated with systemic disease
    - Sarcoid
    - Tuberculosis (TB)
    - Crohn’s disease
    - Bechet’s syndrome

**Search strategy:**

This guideline was produced according to specifications set out in the CEG 21 document ‘Framework for guideline development and assessment’ (2015, 22 updated 2020) accessed at <https://www.bashh.org/_userfiles/pages/files/resources/2020_guidelines_framework.pdf> . It has been updated by reviewing the previous balanoposthitis guideline (2008) and medical literature since its publication using abstracts and articles in the English language up to August 2020. The following sources were reviewed: Medline/Pubmed and Embase, the Cochrane Library (including the Cochrane Database of Systematic Reviews, Database of Abstracts and Reviews of Effects and Cochrane Central Register of Controlled Trials), British Association for Sexual Health and HIV (BASHH) and British Association of Dermatologists (BAD) guidelines (including the previous European guideline for the management of balanitis 2014 and the UK National guideline for the management of balanitis 2008), and the National Institute for Health and Care Excellence (NICE) guidelines. Other relevant guidelines were identified on Google or produced by the US Centres for Disease Control. The evidence reviewed included randomised controlled trials, cohort studies and in the absence of these, case series, case reports and consensus of the writing group. Where there was a paucity of randomised control trials and high-quality evidence for the management of genital manifestations of skin conditions, evidence from other sites was also reviewed by the writing group.

**Search terms:** Balanitis, Balanoposthitis, Penile dermatoses, and specific terms in respect of each condition.

**Sources:** OVID, Medline, PubMed, National Institute for Health, and Care Excellence (NICE), Cochrane Library, Guidelines produced by: IUSTI, BASHH, CDC.

**Equality impact assessment:** An assessment of the guideline and its recommendations was undertaken to ensure the principles of equality and diversity were adhered to.

**Stakeholder involvement, piloting, and feedback:**

The document was reviewed by the Clinical Effectiveness Group of BASHH, and their comments incorporated. The draft guideline was placed on the BASHH website, and any comments received during the consultation period were reviewed by the authors and acted on appropriately. The document was also piloted by target users and the public panel of BASHH, and their feedback considered by the authors.

The guideline was circulated to Fabia Brackenbury (Vulval Health Awareness Campaign and Worldwide Lichen Sclerosus Support) and lay representative on the BASHH Dermatology special interest group, and her comments incorporated.

After publication on the BASHH website the CEG will keep it under review. The guideline will be formally reviewed and updated every 5 years.

Aetiologies

Balanitis is the term for inflammation of the glans penis, and posthitis describes inflammation of the prepuce. In practice both areas are often affected and the term balanoposthitis is then used. It is a common condition affecting up to 20% of uncircumcised men1 but is uncommon after circumcision. In many cases preputial dysfunction is a causal or contributing factor. It is a collection of disparate conditions with similar clinical presentation and varying aetiologies affecting a particular anatomical site (see table 1).

##### **Table 1.** Range of factors causing balanitis 2,3

|  |  |  |
| --- | --- | --- |
| **Infectious** | **Dermatoses** | **Miscellaneous** |
| *Candida spp* | Lichen sclerosus | Trauma |
| *Staphylococcus aureus* | Lichen planus | Poor hygiene |
| Streptococci (Group A and B) | Psoriasis | Penile intraepithelial neoplasia (PeIN) |
| Anaerobes | Circinate balanitis | Systemic disease   * Behçet’s * Crohn’s * Sarcoid * Tuberculosis |
| *Gardnerella vaginalis* | Zoon's balanitis |
| Bacterial STIs   * Chlamydia * Lymphogranuloma venereum * Gonorrhoea * *Mycoplasma genitalium* * Syphilis * Chancroid * Granuloma inguinale | Eczema   * Irritant * Seborrhoeic * Contact allergy |
| Viral STIs   * Herpes simplex * Human papillomavirus | Fixed drug eruption |  |
| Protozoal STIs   * *Trichomonas vaginalis* * *Entamoeba histolytica* | Stevens-Johnson syndrome |
| Parasitic   * Scabies | Immuno-bullous disorders |

Other, rarer dermatoses are not included in this chart.

Infections may be secondary to primary inflammatory dermatoses.

### General Management 2, 3

Clinical Features

The clinical features of balanoposthitis can be divided into local and systemic and primarily include a rash affecting the glans penis and prepuce, which can cause itch. There may be associated changes in colour or texture and sometimes oedema of the skin. If fissuring or ulceration is present, this can be associated with discomfort and dyspareunia. There may also be difficulty retracting the foreskin and a sub-preputial discharge (which can be malodorous). The typical appearances of different conditions are covered in more detail in the individual management sections. Systemic symptoms include rash elsewhere on the body (including mucosal surfaces), joint pains and swelling, lymphadenopathy, and general malaise.

Diagnosis

Balanoposthitis is only a descriptive term, and a more specific diagnosis can often be made from the clinical appearances. However, the appearances should not be considered pathognomonic, particularly as complication by superinfection is common. Biopsy may be required for diagnostic uncertainty or to exclude Penile intraepithelial neoplasia (PeIN)4.

The following investigations aid diagnosis in cases of uncertainty, and onward referral may be required.

1. Sub-preputial swab for *Candida* *spp* and bacterial culture - to exclude an infective cause or superinfection of a skin lesion or dermatosis.
2. Urinalysis for glucose - appropriate in most cases but especially if candidal infection is suspected.
3. *Herpes simplex* virus nucleic acid amplification test (NAAT) - if ulceration present.
4. *Treponemal pallidum* NAAT and /or dark ground examination for spirochaetes if an ulcer is present, with syphilis serology followed up to 3 months.
5. Microscopy or NAAT for *Trichomonas vaginalis* - particularly if a female partner has an undiagnosed vaginal discharge.
6. Screening for other sexually transmitted infections (STIs) - particularly screening for *Chlamydia trachomatis* infection / Non-specific urethritis if a circinate-type balanitis is present.
7. Dermatology opinion for dermatoses and suspected allergy.
8. Urological referral for circumcision or assessment of PeIN or possible malignancy.
9. Biopsy - if the diagnosis is uncertain and the condition persists4.

General Management

The aims of diagnosis and treatment are to identify and manage patient symptoms, to diagnose and treat any related sexually transmitted disease, to minimise sexual dysfunction, to minimise urinary dysfunction, to treat pre-malignant disease and exclude penile cancer. The identification of any underlying diagnosis is also important in providing the patient with detailed information about the natural history and long-term health implications or their condition (such as risk of malignancy) and any risk to their partner if an STI is identified.

As predisposing factors for balanoposthitis include both poor hygiene and overwashing5, advice should be given on good genital skin care, personal hygiene, and avoidance of soaps. The use of emollients as soap substitutes should be encouraged. Patients should be warned of effects on condoms if creams are applied. Management of other predisposing factors such as a non-retractile foreskin and systemic conditions such as diabetes should be optimised and the role of circumcision6 should be discussed.

**INFECTIVE CAUSES**

Balanoposthitis may be caused by infectious agents 7, 8, both sexually and non-sexually transmitted (although some of the latter may be sexually transmissible) as shown in Table 1. If an STI is suspected as a cause, a full screen for common STIs should be done. There is also an association between carriage of organisms and increased risk of Human Immunodeficiency virus (HIV) infection9. However, the presence of an infective agent on swabbing does not confirm causality as superinfection of other skin conditions is common. Follow up is not generally needed.

**Candidal balanoposthitis**

Clinical Features

Patients generally present with an erythematous rash which may be associated with itch and/or soreness. The typical appearance is of blotchy erythema with small papules, which can be eroded, or of dull red areas with a glazed appearance. In severe cases the whole of the glans and prepuce may be involved. It is commoner with increasing age10 and can be the presenting sign of diabetes mellitus.

Diagnosis

The presence of *Candida spp* can be confirmed by sub-preputial culture, but other dermatoses should be excluded as the presence of *Candida spp* is most commonly an opportunistic infection. Similar appearances can be seen with irritant and non-specific balanoposthitis.

Urinalysis for glucose should be considered, as should investigation for causes of immunosuppression, if the balanitis is severe or persistent.

Management

Although there has been an increase in reports of drug resistance in serious candidal infection, there is no new evidence pertaining to treatment of candidal balanitis. Hygiene measures should be recommended as above. As there is a high rate of candidal infection in sexual partners, treatment of symptomatic partners can be considered (2, D).

Recommended regimens11

* Clotrimazole cream 1%12(I, A)
* Miconazole cream 2%13(2, B)

Apply twice daily for 7-14 days.

Alternative regimens

* Fluconazole 150mg stat orally12(I, A)- if symptoms severe
* Nystatin cream13 100,000 units/gm - if resistance suspected, or allergy to imidazoles (2, B)
* Topical imidazole with 1% hydrocortisone - if marked inflammation is present11(2, D)

**Anaerobic infection** 14

Clinical features

Characteristic features include the presence of foul-smelling odour and sub-preputial discharge, which may be associated with superficial erosions, oedema, and tender lymphadenopathy in severe cases. There is an association with phimosis.

Diagnosis

The diagnosis may be made clinically, but gram stain may show fusiform bacteria or a mixed bacterial picture. Culture may not be helpful, although *Gardnerella vaginalis* (a facultative anaerobe) may be isolated. Sub-preputial NAAT should be taken to exclude other causes such as *Trichomonas vaginalis* or *Herpes simplex* (if ulcerated).

Management

If phimosis is present, circumcision may be required to prevent recurrence, and advice should be given about genital hygiene.

Recommended regimen

* Metronidazole 400 - 500mg twice daily x 1 week (1, D). The optimum dosage schedule for treatment is unknown.
* Milder cases may respond to topical metronidazole.

Alternative regimen

* Co-amoxiclav 375mg three times daily x 1 week.
* Clindamycin cream applied twice daily until resolved.

These treatments have not been assessed in clinical trials (2, D).

**Aerobic infection**

Clinical Features

The presence of erythema +/- oedema and purulent discharge may suggest an infective aetiology.

Diagnosis

This is dependent on the isolation of a potential causative organism on sub-preputial culture. *Streptococcus spp and Staphylococcus aureus* have been reported as causing balanitis 7, 8, 15 although other organisms may also be involved. Superinfection of an underlying dermatosis rather than a primary infective balanitis should also be considered.

Management

Hygiene measures and topical treatment may be sufficient for milder cases, but more severe cases (i.e. if oedematous or if Group A Streptococci isolated) warrant systemic treatment and would depend on the sensitivities of the isolate.

Recommended regimens (2, D)

* Mupirocin ointment 2-3 times per day for 7-10 days16
* Trimovate cream once or twice daily for 7-10 days
* Severe cases may require systemic antibiotics while awaiting culture results16,18.
* Consider prescribing oral phenoxymethylpenicillin 500 mg four times a day for 10 days while awaiting swab results.
* Oral clarithromycin 250 mg twice daily for seven days

**Balanoposthitis relating to STIs**

Balanoposthitis can be a feature of many STIs (see table 1). The following section describes the presentation of balanoposthitis relating to specific STIs. For further diagnostic and management information please refer to BASHH guidelines for each condition.

**Chlamydia (D-K serovars)**

Clinical Features

Chlamydial infection is associated with circinate balanitis, which is a feature in 40% of cases of reactive arthritis17. It presents as erythematous annular shallow erosions with raised borders and surface covered with yellowish white scaly areas. There may also be a serpiginous annular lesion that often has a greyish white granular appearance that may form geographical patterns17,18.

Diagnosis

The diagnosis of chlamydial circinate balanitis is based on the clinical appearance with an associated positive NAAT for chlamydia. Histology should not be undertaken routinely but shows spongiform pustules seen in the upper epidermis and resembles that of pustular psoriasis. The diagnosis may be supported by HLA B27 positivity.

Management

Chlamydial infection should be managed as per BASHH guidelines19. Skin lesions should be managed as for Psoriasis (see subsequent section).

**Lymphogranuloma Venereum (LGV)**

Clinical Features

The genital form of LGV causes transient superficial herpetiform ulcers on coronal sulcus, prepuce, glans & scrotum in men. Penile oedema may result in varying degrees of phimosis20 although balanitis is a recognised but uncommon type of primary lesion in LGV 21.

Diagnosis and Management 22, 23

Refer to guidelines22, 23.

**Gonorrhoea**

Clinical Features

Gonococcal balanoposthitis can rarely be the primary manifestation and ischaracterized by tender ulcers, pustules, or furuncles on the prepuce or shaft of the penis24. Abscesses of the prepuce and ulceration of glans penis have also been reported, but are rare 25, 26. It can also cause preputial oedema and erythema in men with urethritis27. Recurrent gonococcal balanoposthitis may result in secondary hypopigmentation of the glans 28.

Diagnosis and Management

Refer to BASHH guidelines 29.

**Mycoplasma**

Clinical Features

There is a significant correlation of *Mycoplasma genitalium* with development of balanitis/posthitis, usually in association with urethritis30. *Mycoplasma genitalium* can present as a non-specific balanitis and/or posthitis, and erythematous or circinate lesions with a tendency for haemorrhage may be seen 31. Balanitis may also occur in the absence of urethral discharge30.

Diagnosis and management

Refer to BASHH guidelines32.

**Syphilis**

Clinical Features

Syphilitic Balanitis of Follman is an uncommon presentation of primary syphilis and is.

described as erosive balanitis with a bright red glans and foreskin, with multiple oozing superficial erosions and associated with palpable non-tender lymph nodes 33.

Features may be variable and can also include oedema and dark red erythema over the glans penis 34, 35, diffuse induration of the glans penis 34, 35, 36, 37. Erosions, crusted or scaly lesions and coalescent white / pink papules and circinate lesions have also been described 35, 36, 38, 39, 40.

Syphilitic balanoposthitis has been reported at all stages of infectious syphilis and may not always present with a concomitant chancre. 33, 35, 36, 37, 41, 42

Diagnosis and Management

Balanitis can be the sole clinical feature of primary syphilis. Syphilis should be suspected in cases of balanoposthitis, particularly when there is induration of the glans penis and lymphadenopathy. Dark field microscopy or NAAT should be undertaken where possible and syphilis serology should be performed. Diagnosis of syphilitic balanoposthitis requires the exclusion of other infections.

For further details of diagnosis and management refer to BASHH guidelines43.

**Chancroid**

Clinical Features

Lesions begin as tender erythematous papules on prepuce and frenulum in men which then ulcerate. Balanoposthitis develops from the irritant effects of by purulent discharge from untreated lesions in uncircumcised men 44.

Diagnosis and Management

Refer to BASHH guidelines 45.

**Granuloma Inguinale**

Clinical Features

Balanoposthitis may be caused by the purulent exudate from fleshy granulomatous ulcers affecting the foreskin or glans. The lesions themselves are painless, non-indurated and covered with friable granulation tissue.

Diagnosis and Management

Refer to BASHH guidelines 46.

**Genital Herpes simplex virus infection**

Clinical Features

Typical lesions of herpes may rarely develop into a necrotising balanitis 47, 48. This is characterised by eschars, pustules and purulent discharge on the glans and erythema and oedema of the glans, prepuce, and shaft. Immunosuppressed patients may develop chronic ulceration, crusted and verrucous lesions.

Diagnosis and Management

Refer to BASHH guidelines 49.

**Human Papillomavirus (HPV) infection**

Clinical Features

Balanoposthitis has been associated with subclinical HPV infection of the glans and prepuce. This is commoner in uncircumcised men with a history of prior treatment for warts, and can present with redness, itching, burning, tenderness, and dyspareunia. It may cause macular lesions, fissuring and rarely, penile oedema and adenopathy50, 51.

Diagnosis

HPV should be considered in the pathogenesis of chronic and/or recurrent balanoposthitis. Usually a clinical diagnosis is made from recognition of characteristic lesions although dermatoscopy/penoscopy may be helpful (if available). Rarely, biopsy may be required to confirm the diagnosis in atypical lesions. HPV detection or typing does not influence management and is not recommended 52.

Management

Refer to BASHH guidelines 53.

**Human Immunodeficiency Virus (HIV) infection**

HIV may be associated with balanoposthitis, particularly circinate balanitis, which may be in a more severe form. Other forms of balanitis have also presented in HIV infection but no specific HIV related balanoposthitis is reported. There is also an association between carriage of organisms and increased risk of Human Immunodeficiency virus (HIV) infection9.

**Trichomoniasis**

Clinical Features

Balanoposthitis may occur in approximately one third of male carriers of *Trichomonas vaginalis (TV),* and a long prepuce has been found to be a predisposing factor54. It typically causes an erosive balanitis, but ulcerative forms can also occur. Patients may also have an associated urethritis, and inguinal adenopathy54, 55.

Diagnosis

Diagnosis can be confirmed by identification of TV from the sub-preputial space in a wet preparation or by NAAT.

Management

Refer to BASHH guidelines 56.

**Scabies**

Clinical Features

Scabetic balanitis can present with erythematous, excoriated papules and nodules with pustules secondary to bacterial infection 57. Bullous lesions have also been described 58,59.

Diagnosis and Management

Diagnosis is dependent on identification of pathognomonic lesions in association with balanitis.

Refer to BASHH guidelines 60.

**DERMATOLOGICAL PRESENTATIONS (see Figure 1)**

**Pallor**

**Lichen sclerosus** typically reveals pale or white patches on the glans, often with involvement of the prepuce. Architectural changes such as blunting of the coronal sulcus, phimosis or ‘wasting’ of the prepuce, and meatal narrowing.

Differential diagnosis of pallor: vitiligo – this present without any inflammation or structural change.

**Initial management:** Ultra-potent topical steroids (e.g. clobetasol propionate 0.05% ointment) applied once daily for up to 3 months (reducing course) until remission, then gradually reduce to a maintenance dose.64, 65,

72

**Complications:** superinfection, penile cancer.

Further management and guidelines: ref 61-76

**Well demarcated erythema**

**Lichen planus**77-89.

Characteristic clinical appearance on keratinised skin is of polygonal violaceous papules, which may be itchy and associated with white reticulate surface (Wickham’s striae), with linear lesions exhibiting Koebner’s phenomenon. Annular white patches and erosive lesions can occur on mucosal surfaces.

**Initial management**:

Moderate to ultrapotent topical steroids depending on severity84,85 (1, B)

E.g. Clobetasol propionate ointment or cream applied daily for 4 weeks then reducing in frequency over the next 8 weeks depending on response.

**Complications**: phimosis, dysplasia / squamous ca

Further management and guidance: ref 77-89

**Zoon’s**90-101

Appearance includes well circumscribed orange–red glazed areas with multiple pinpoint redder spots - “cayenne pepper spots” on the glans and contiguous inner aspect of the prepuce in a symmetrical pattern.

**Initial management**93,94: consider topical steroid preparations with or without added antibacterial agents e.g. Clobetasol proprionate or Trimovate cream, applied once or twice daily (1, D) and refer for circumcision93.

**Complications**: missing diagnosis of PeIN / SCC

Further management and guidance: ref 90-101

**Psoriasis and circinate balanitis**102-107

The lesions are characteristically well demarcated, and in the circumcised male, psoriasis on the glans is similar in appearance to the condition elsewhere, presenting with red scaly plaques. However, in uncircumcised men, scaling is lost, and the patches appear red and glazed. The clinical features of circinate balanitis are described under chlamydial infection.

**Initial management**: Moderate potency topical steroids104,105 (+/- antibiotic and antifungal) (1, C)

Further management and guidance: ref 102-107

**Fixed drug eruptions**108-110

The lesions are usually well demarcated and erythematous but can be bullous with subsequent ulceration. As the inflammation settles there may be post-inflammatory hyperpigmentation.

**Initial management**: Lesions will settle without treatment when the precipitant is discontinued, but mild to moderate strength topical steroids may be required for symptomatic relief115(1, C).

**Penile intraepithelial neoplasia**111-137

These are an important differential diagnosis and should be considered for any non-resolving lesion. They are now classified as differentiated and undifferentiated PeIN – the latter more commonly affecting the glans and having a greater risk of malignant transformation.

Lesions vary in clinical appearance:

* small warty/papillomatous papules, usually appearing on the lower shaft or base of the glans penis and surrounding pubic region. Lesions are usually multiple. (Previously known as Bowenoid papulosis)
* warty, scaly, and eczematous or psoriatic appearance erythematous patch. (Previously known as Bowen’s disease)
* A ‘glazed’ or ‘velvety’ red patch. (Previously known as Erythroplasia of Queyrat). Risk of progression to invasive cancer appears relatively high if untreated; almost a third of patients.129

**Management:** Patients should be referred to Uro-Oncology multidisciplinary pathways (1, A).

Further management and guidance: ref 111-137

**Poorly demarcated erythema**

**Eczema**

**Seborrhoeic dermatitis**138-140

Seborrhoeic dermatitis can cause non-specific redness and itch, without the scale seen at non genital sites. Seborrhoeic dermatitis classically affects other sites such as nasolabial folds, scalp, ears, and eyebrows.

**Initial management**: Antifungal cream with a mild to moderate steroid (1, D).

Further management and guidance: There is a paucity of evidence specifically for balanitis, and low-quality evidence for other sites138-140.

**Irritant /Allergic Eczema**141-144

Irritant balanoposthitis is commonly associated with frequent washing of the genital area with soap and is associated with fragrances and preservatives. There may be a history of atopy. Patients usually present with itch and redness, and the appearances can vary in severity from mild erythema to widespread oedema of the penis.

**Initial management**: Patients should be advised to avoid soaps and other precipitants, and to use emollients as soap substitutes and as required. Recurrent problems are common, and the patients need to be informed of this.

Recommended Regimen

* Hydrocortisone 1% applied once or twice daily until resolution of symptoms. (1C,)
* In more florid cases more potent topical steroids may be required and may need to be combined with antifungals and/or antibiotics
* Calcineurin inhibitors may be useful (II, b) 114, but onward referral is recommended “

Further management: refs 138-144

Fig 1 Dermatological presentations

**Balanitis associated with Systemic disease** 145-166

Whilst the majority of genital skin presentations are likely to be sexually transmitted or specific dermatoses, it is important to consider other systemic causes in the differential diagnoses, especially in lesions refractory to treatment or those at low risk of STIs.

Below is a list of alternative causes of genital lesions that should be considered so that they can be appropriately identified and referred on to the appropriate specialty (1, D).

**Sarcoid**  
Sarcoid has been reported to cause ulcerative lesions of the penis,145 as well as pink/purple annular eczema-like plaques and papules associated with pruritus and oedema 146-148.

**Tuberculosis (TB)**  
  
TB tends to present as small, shallow genital ulceration with either singular or multiple lesions, sometimes with sinus tract formation. Very rarely, it can result in elephantiasis of the genitals149-151.

**Crohn’s Disease**  
  
Crohn’s of the genital region can present as genital ulceration, balanitis and phimosis or genital oedema 152-154.

**Behçet’s Syndrome**

BS-related genital aphthous ulcers typically start as a tender nodule, becoming a round, deep and painful ulcer (0.5cm to over 3cm), interfering with sitting, walking, and causing sexual dysfunction155-166.

CONSIDERATION OF RESOURCE IMPLICATIONS

It is acknowledged that some tests and treatments may not be available in all settings. Where biopsy is not available these patients should be referred to Dermatology. We recommend if malignancy is considered to refer on 2WW cancer pathway.

Some treatment preparations, e.g. Topical vit D preparations, may not be available on local formularies. It is advised that such preparations are discussed with MDT before prescribing.

QUALIFYING STATEMENT

The recommendations in this guideline may not be appropriate for use in all clinical situations. Decisions to follow these recommendations must be based on the professional judgement of the clinician and consideration of individual patient circumstances and available resources. It is acknowledged that not all departments will have specific genital dermatology provision.

All possible care has been taken to ensure the publication of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing physician to ensure the accuracy and appropriateness of the medication they prescribe.

**Recommendations for further research**

Further research is recommended on the optimum regimes for treatment of skin conditions in genital skin.

**Acknowledgements**

The guideline was circulated to Fabia Brackenbury (Vulval Health Awareness Campaign and Worldwide Lichen Sclerosus Support) and lay representative on the BASHH Dermatology special interest group, and her comments incorporated.

**References**

1. Morris BJ, Krieger JN. Penile Inflammatory Skin Disorders, and the Preventive Role of Circumcision. *Int J Prev Med*. 2017; 8:32.
2. Edwards S, Bunker C. Chapter 7: Other conditions affecting the male genitalia. In: Rogstad K (ed.) *ABC of Sexually Transmitted Infections*. 6th ed. Oxford: Wiley-Blackwell; 2011. p.35-41.
3. Bunker CB. *Male Genital Skin Disease*. E-book: W B Saunders Co Ltd; 2004.
4. Rao A, Bunker CB. Male genital skin biopsy. *Int J STD & AIDS.* 2011;22(7): 418-9.
5. Birley HDL, Walker MM, Luzzi GA et al. Clinical features and management of recurrent balanitis: association with atopy and genital washing. *Genitourinary Medicine.* 1993; 69:400-403.
6. Mallon E, Hawkins D, Dinneen M, Francics N, Fearfield L, Newson R, Bunker C. Circumcision, and genital dermatoses. *Arch Dermatol.* 2000;136:350-354.
7. Alsterholm M, Flytström I, Leifsdottir R, Faergemann J, Bergbrant IM. [Frequency of bacteria, Candida and malassezia species in balanoposthitis.](http://www.ncbi.nlm.nih.gov/pubmed/18709300) *Acta Derm Venereol*. 2008;88(4):331-6.
8. Lisboa C, Ferreira A, Resende C, Rodrigues AG. [Infectious balanoposthitis: management, clinical and laboratory features.](http://www.ncbi.nlm.nih.gov/pubmed/19200183) *Int J Dermatol*. 2009;48(2):121-4.
9. Onywera H, Williamson AL, Cozzuto L et al. The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection. *BMC Microbiol.* 2020;20(1):78*.*
10. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candidal balanitis: risk factors. *J Eur Acad Dermatol Venereol*. 2010;24(7):820-6.
11. National Institute for Health and Care Excellence (NICE), *Clinical Knowledge Summaries.* *Candida – skin*. April 2025. <https://cks.nice.org.uk/candida-skin> (Accessed: 20/08/2025).
12. Stary A, Soeltz-Szoets J, Ziegler C, Kinghorn GR, Roy RB. Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis. *Genitourin Med.* 1996;72(2):98-102.
13. Forster GE, Harris JRW. Double blind therapeutic trial in balanitis – miconazole and nystatin. *Eur J Sex Transm Dis*. 1986;3:81-83.
14. Ewart Cree G, Willis AT, Phillips KD, Brazier JS. Anaerobic balanoposthitis. *BMJ.* 1982;284:859-860.
15. Minami M, Wakimoto Y, Matsumoto M, Matsui H, Kubota Y, Okada A, Isaka M, Tatsuno I, Tanaka Y, Hasegawa T. [Characterization of Streptococcus pyogenes isolated from balanoposthitis patients presumably transmitted by penile-oral sexual intercourse.](http://www.ncbi.nlm.nih.gov/pubmed/20107992) *Curr Microbiol*. 2010;61(2):101-5.
16. National Institute for Health and Care Excellence (NICE). *Clinical Knowledge Summaries CKS. Balanitis.* May 2024. <https://cks.nice.org.uk/balanitis> (Accessed: 20/08/2025).
17. Wray AA, Velasquez J, Leslie SW, et al. *Balanitis*. Updated 31st August 2024. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. <https://www.ncbi.nlm.nih.gov/books/NBK537143/>
18. Edwards SK, Bunker CB, van der Snoek EM, van der Meijden WI. 2022 European guideline for the management of balanoposthitis. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1104-1117.
19. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. *Int J STD AIDS*. 2016;27(4):251-267. Updated 26th Sept 2018. <https://www.bashh.org/guidelines/>
20. John L Kiley et al. Lymphogranuloma Venereum (LGV) Clinical Presentation. https://emedicine.medscape.com/article/220869-clinical#b4 (Accessed 20/08/2025).
21. Coutts WE. Lymphogranuloma venereum; a general review. *Bull World Health Organ*. 1950;2(4):545-562.
22. de Vries HJC, de Barbeyrac B, de Vrieze NHN, et al. 2019 European guideline on the management of lymphogranuloma venereum. *J Eur Acad Dermatol Venereol*. 2019;33(10):1821-1828.
23. White J, O'Farrell N, Daniels D. British Association for Sexual Health, and HIV. 2013 UK National Guideline for the management of lymphogranuloma venereum: Clinical Effectiveness Group of the British Association for Sexual Health and HIV (CEG/BASHH) Guideline development group. *Int J STD AIDS*. 2013;24(8):593-601.
24. [Haim](https://www.ncbi.nlm.nih.gov/pubmed/?term=Haim%20S%5BAuthor%5D&cauthor=true&cauthor_uid=4990377) S, [Merzbach](https://www.ncbi.nlm.nih.gov/pubmed/?term=Merzbach%20D%5BAuthor%5D&cauthor=true&cauthor_uid=4990377) D. Gonococcal penile ulcer. [*Br J Vener Dis*](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1048093/)*.* 1970 Aug;46(4):336–337.
25. Rosen T. Unusual presentations of gonorrhea. *J Am Acad Dermatol.* 1982;6:369–72.
26. [Neubert](https://pubmed.ncbi.nlm.nih.gov/?term=Neubert+U&cauthor_id=3928269) U, [Korting](https://pubmed.ncbi.nlm.nih.gov/?term=Korting+HC&cauthor_id=3928269) HC, [Luderschmidt](https://pubmed.ncbi.nlm.nih.gov/?term=Luderschmidt+C&cauthor_id=3928269) C, [Braun-Falco](https://pubmed.ncbi.nlm.nih.gov/?term=Braun-Falco+O&cauthor_id=3928269) O. Preputial abscesses caused by beta-lactamase-producing gonococci. *Cutis.*1985;36(2):161-163.
27. Fiumara NJ, Kahn S. Contact dermatitis from a gonococcal discharge: a case report. *Sex Transm Dis*. 1982;9(1):41-42.
28. Abdul Gaffoor PM. Hypopigmentation of the glans penis. *Cutis*. 1983;31(2):214.
29. Fifer H, Ismail MA, Soni S, Nwaosu U, Sadiq ST, Milligan A, Saunders J, Medland N. British Association of Sexual Health, and HIV UK National Guideline for the Management of infection with Neisseria gonorrhoeae, 2025. *Int J STD AIDS*. 2025 May 31:9564624251345195. <https://www.bashh.org/guidelines/>
30. Horner PJ, Taylor-Robinson D. [Association of Mycoplasma genitalium with balanoposthitis in men with non-gonococcal urethritis.](http://www.ncbi.nlm.nih.gov/pubmed/20852310) *Sex Transm Infect.* 2011;87(1):38-40.
31. Siboulet A, Catalint F, Deubel M. Balanitis et mycoplasma. *Bull Soc Fr Dermatol Syphiligr.* 1975;82:419-422.
32. Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV national guideline for the management of infection with *Mycoplasma genitalium* (2018). *Int J STD AIDS*. 2019;30(10):938-950. <https://www.bashh.org/guidelines/>
33. Follmann E. Le problème de la balanite syphilitique. *Ann Dermatol Syph.* 1948;8:470-483.
34. Degos R. Present-days aspects of primo-secondary syphilis. *Rev Médecine*. 1970; 23:1333–1341.
35. Oanţă A, Irimie M. Syphilitic balanitis of Follmann. *Int J Dermatol*. 2014;53(7):830-831.
36. Abdennader S, Janier M, Morel P. Syphilitic balanitis of Follmann: three case reports. *Acta Derm Venereol*. 2011;91(2):191– 192.
37. Rovira-López R, García-Martínez P, Martín-Ezquerra G, Pujol RM, Aventín DL. Balanoposthitis and Penile Edema: Atypical Manifestations of Primary Syphilis. *Sex Transm Dis*. 2015;42(9):524-525.
38. Mainetti C, Scolari F, Lautenschlager S. The clinical spectrum of syphilitic balanitis of Follmann: report of five cases and a review of the literature. *J Eur Acad Dermatol Venereol*. 2016;30(10):1810-1813.
39. Babu CS, Vitharana S, Higgins SP. Primary syphilis presenting as balanitis. *Int J STD AIDS*. 2007;18(7):497-498.
40. Lejman K, Starzycki Z. Syphilitic balanitis of Follmann developing after the appearance of the primary chancre. A case report. *Br J Vener Dis*. 1975; 51(2): 138–140.
41. Waugh MA. Balanitis. *Dermatol Clin.* 1998;16(4):757–62.
42. Korta DZ, Lewin JM, Patel RR, et al. Acute syphilitic balanitis and gross penile edema in an HIV-infected man. *Global J Dermatol Venereol.* 2013;1:18–20.
43. Kingston M, Apea V, Evans C, Fifer H, Foster K, Patrick P, Grant A, Manns V, Ramsden S, Sinka K, Sukthankar A, Sullivan A, Tyler S. BASHH UK guidelines for the management of syphilis 2024. *Int J STD AIDS*. 2024 Dec;35(14):1142-1160. <https://www.bashh.org/guidelines/>
44. Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. *Sex Transm Infect*. 2003;79:68-71.
45. O'Farrell N, Lazaro N. UK National Guideline for the management of Chancroid 2014. *Int J STD AIDS*. 2014;25(14):975-983. <https://www.bashh.org/guidelines/>
46. O'Farrell N, Hoosen A, Kingston M. 2018 UK national guideline for the management of donovanosis. *Int J STD AIDS*. 2018;29(10):946-948. <https://www.bashh.org/guidelines/>
47. Powers RD, Rein MF, Hayden FG. Necrotizing balanitis due to herpes simplex type 1. *JAMA*. 1982;248(2):215-216.
48. Peutherrer JF, Smith IW, Robertson DHH. Necrotising balanitis due to a generalized primary infection with herpes simplex virus type 2. *Br J Venerol Dis*. 1979;55(1):48-51.
49. Patel R, Green J, Moran B, Clarke E, Seneviratne K, Evans C, Young F, Nicholson M, Pelosi E, Kingston M, Foley E. British Association of Sexual Health, and HIV UK national guideline for the management of anogenital herpes, 2024. *Int J STD AIDS*. 2025 Feb;36(2):90-105. <https://www.bashh.org/guidelines/>
50. Wikström A, von Krogh G, Hedblad MA, Syrjänen S. Papillomavirus-associated balanoposthitis. *Genitourin Med*. 1994;70(3):175-181.
51. Löwhagen GB, Bolmstedt A, Ryd W, et al. The prevalence of "high-risk" HPV types in penile condyloma-like lesions: correlation between HPV type and morphology. *Sexually Transmitted Infections.* 1993;69:87-90.
52. Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. *J Eur Acad Dermatol Venereol*. 2020;34(8):1644-1653.
53. Nugent D, Apoola A, Coleman H, Gilmour C, Lawton MD, Nori A, D C Ross J, Whitlock G, Yeend-Curd-Trimble H. British association for sexual health and HIV national guideline for the management of anogenital warts in adults (2024). *Int J STD AIDS*. 2024 Jun;35(7):498-509. <https://www.bashh.org/guidelines/>
54. Michalowski R. Balano-posthites à Trichomonas. A propos de 16 observations [Trichomonal balano-posthitis. Report of 16 cases (author's transl)]. *Ann Dermatol Venereol*. 1981;108(10):731-738.
55. English JC 3rd, Laws RA, Keough GC, Wilde JL, Foley JP, Elston DM. Dermatoses of the glans penis and prepuce. *J Am Acad Dermatol*. 1997;37(1):1-24;quiz 25-6.
56. Sherrard J, Pitt R, Hobbs KR, Maynard M, Cochrane E, Wilson J, Tipple C. British Association for Sexual Health, and HIV (BASHH) United Kingdom national guideline on the management of Trichomonas vaginalis 2021. *Int J STD AIDS.* 2022 Jul;33(8):740-750. <https://www.bashh.org/guidelines/>
57. Elgart ML. Scabies. *Dermatol Clin*. 1990;8(2):253-263.
58. Viraben R, Dupre A. Scabies mimicking bullous pemphigoid. *J Am Acad Dermatol*. 1989;20(1):134-136.
59. Chapel TA, Krugel L, Chapel J, Segal A. Scabies presenting as urticaria. *JAMA*. 1981;246(13):1440-1441.
60. Morris G, Haddow L, Sashidharan P.N., Savary-Trathen A, Soni S, Bigland C, Mirza H, Walker S.L. British Association for Sexual Health, and HIV National Guideline on the Management of Scabies in adults 2025. *Int. J. STD AIDS*. 2025;36:516-532. <https://www.bashh.org/guidelines/>
61. Bunker CB, Shim TN. Male genital lichen sclerosus. *Indian J Dermatol*. 2015;60(2):111–7.
62. Bunker CB, Patel N, Shim TN. Urinary voiding symptomatology (micro-incontinence) in male genital lichen sclerosus. *Acta Derm Venereol.* 2013;93(2):246-8.
63. Hofer MD, Meeks JJ, Mehdiratta N. Granieri MA, Cashy J, Gonzalez CM. Lichen sclerosus in men is associated with elevated body mass index, diabetes mellitus, coronary artery disease and smoking. *World J Urol.* 2014;32(1):105-8.
64. Kravvas G, Shim TN, Doiron PR et al. The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients. *J Eur Acad Dermatol Venereol.* 2018;32(1):91-95*.*
65. Lewis FM, Tatnall FM, Velangi SS et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. *Br J Dermatol.* 2018;178(4):839-853*.*
66. Kirtschig G, Becker K, Günthert A et al. Evidence‐based (S3) Guideline on (anogenital) Lichen sclerosus. *J Eur Acad Dermatol Venereol.* 2015;29(10):e1-43*.*
67. Edmonds EV, Hunt S, Hawkins D, Dinneen M, Francis N, Bunker CB. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. *J Eur Acad Dermatol Venereol.* 2012;26(6):730-7*.*
68. Kantere D, Löwhagen GB, Alvengren G, Månesköld A, Gillstedt M, Tunbäck P. The clinical spectrum of lichen sclerosus in male patients - a retrospective study*. Acta Derm Venereol.* 2014;94(5):542‐6.
69. Powell J, Robson A, Cranston D et al. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. *Br J Dermatol.* 2001;145(1):85–9.
70. Pietrzak P, Hadway P, Corbishley CM, et al. Is the association between balanitis xerotica obliterans and penile carcinoma underestimated? *BJU Int*. 2006;98(1):74–6.
71. Philippou P, Shabbir M, Ralph DJ, et al. Genital lichen sclerosus/balanitis xerotica obliterans in men with penile carcinoma: a critical analysis. *BJU Int*. 2013; 111(6):970-6.
72. Piris A, Sanchez DF, Fernandez-Nestosa MJ, et al. Topographical Evaluation of Penile Lichen Sclerosus Reveals a Lymphocytic Depleted Variant, Preferentially Associated With Neoplasia: A Report of 200 Cases. *Int J Surg Pathol*. 2020;28(5):468-476.
73. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus. *Cochrane Database of Systematic Reviews.* 2011(12):CD008240.
74. Dahlman-Ghozlan K, Hedblad MA, von Krogh G. Penile lichen sclerosus et atrophicus treated with clobetasol diproprionate 0.05% cream: a retrospective clinical and histopathological study. *J Am Acad Dermatol.* 1999;40(3):451-7.
75. Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64(6):e99-104.
76. Kulkarni S, Barbagli G, Kirpekar D, Mirri F, Lazzeri M. [Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients.](http://www.ncbi.nlm.nih.gov/pubmed/18691809) *Eur Urol.* 2009 Apr;55(4):945-54.
77. Petruzzi M, De Benedittis M, Pastore L, Grassi FR, Serpico R. Peno-gingival lichen planus. *J Periodontol*. 2005 Dec;76(12):2293-8.
78. Mallon E, Hawkins D, Dinneen M, *et al*. Circumcision and Genital Dermatoses. Arch Dermatol. 2000;136(3):350–354.
79. Halevy S, Shai A. Lichenoid drug eruptions. *J Am Acad Dermatol*. 1993;29:249-55.
80. Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. *Front Pharmacol*. 2019;10:282.
81. Itin PH, Hirsbrunner P, Büchner S. Lichen planus: an unusual cause of phimosis. *Acta Derm Venereol*. 1992;72(1):41-2.
82. Kristiansen S, Svensson Å, Drevin L *et al*. Risk Factors for Penile Intraepithelial Neoplasia: A Population-based Register Study in Sweden, 2000–2012. *Acta Derm Venereol.* 2019;99(3):315–320.
83. de Oliveira Leal M L, *et al.* Penile squamous cell carcinoma and lichen planus. *Surg Exp Pathol*. 2020;3:1-3.
84. Irvine C, Irvine F, Champion RH. Long-term follow-up of lichen planus. *Acta Derm Venereol*. 1991;71(3):242-4.
85. Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, Murphy R. Interventions for erosive lichen planus affecting mucosal sites. *Cochrane Database Syst Rev.* 2012(2):CD008092.
86. Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. *J Eur Acad Dermatol Venereol*. 2019;33(10):1847‐62.
87. [Volz T](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Volz%20T%22%5BAuthor%5D), [Caroli U](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Caroli%20U%22%5BAuthor%5D), [Lüdtke H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22L%C3%BCdtke%20H%22%5BAuthor%5D), et al. Pimecrolimus cream 1% in erosive oral lichen planus-a prospective randomized double-blind vehicle-controlled study. [*Br J Dermatol.*](http://www.ncbi.nlm.nih.gov/pubmed/18647310##) 2008; 159(4):936-41.
88. Poon F, De Cruz R, Hall A. Acitretin in erosive penile lichen planus. *Australas J Dermatol*. 2017;58(3):e87-e90.
89. [Porter WM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Porter%20WM%22%5BAuthor%5D), [Dinneen M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dinneen%20M%22%5BAuthor%5D), [Hawkins DA](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hawkins%20DA%22%5BAuthor%5D), [Bunker CB](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bunker%20CB%22%5BAuthor%5D). Erosive penile lichen planus responding to circumcision. [*J Eur Acad Dermatol Venereol.*](http://www.ncbi.nlm.nih.gov/pubmed?term=J%20Eur%20Acad%20Dermatol%20Venereol.%202001%20May%3B15(3)%3A266-8.%20Erosive%20penile%20lichen%20planus%20responding%20to%20circumcision.%20) 2001;15(3):266-8.
90. ZOON JJ. Balanoposthite chronique circonscrite bénigne à plasmocytes [Chronic benign circumscript plasmocytic balanoposthitis]. *Dermatologica*.1952;105(1):1-7.
91. Bunker CB. Zoon balanitis – does it exist? *J Eur Acad Dermatol Venereol*. 2020; 34(3):e116-117.
92. Weyers W, Ende Y, Schalla W, Diaz-Cascajo C. Balanitis of Zoon: a clinicopathologic study of 45 cases. *Am J Dermatopathol*. 2002;24(6):459-67.
93. Kumar B, Sharma R, Rajagopalan M, Radothra BD. Plasma cell balanitis: clinical and histological features - response to circumcision. *Genitourin Med.* 1995;71(1):32-4.
94. Tang A, David N, Horton LW. Plasma cell balanitis of Zoon: response to Trimovate cream. *Int J STD AIDS*. 2001;12(2):75-8.
95. Cohen PR. Topical mupirocin 2% ointment for diagnosis of Zoon's balanitis and monotherapy of balanitis circumscripta plasmacellularis. *Int J Dermatol*. 2019; 58(6):e114-e115.
96. Lee MA, Cohen PR. Zoon Balanitis Revisited: Report of Balanitis Circumscripta Plasmacellularis Resolving With Topical Mupirocin Ointment Monotherapy. *J Drugs Dermatol*. 2017;16(3):285–287.
97. Bari O, Cohen PR. Successful management of Zoon's balanitis with topical mupirocin ointment: a case report and literature review of mupirocin‐responsive balanitis circumscripta plasmacellularis. *Dermatol Ther*. 2017;7(2):203–210.
98. Roe E, Dalmau J, Peramiquel L, Perez M, Lopex-Lozano HE, Alomar A. Plasma cell balanitis of zoon treated with topical tacrolimus 0.1%: report of three cases. *J Eur Acad Dermatol Venereol*. 2007;21(2):284-5.
99. Bardazzi F, Antonucci A, Savoia F, Balestri R. Two cases of Zoon's balanitis treated with pimecrolimus 1% cream. *Int J Dermatol*. 2008;47(2):198-201.
100. Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). *Clin Epidemiol*. 2018;10:299-310.
101. Retamar RA, Kien MC, Chouela EN. Zoon’s balanitis: presentation of 15 patients, five treated with a carbon dioxide laser. *Int J Dermatol*. 2003;42(4):305-7.
102. Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol*. 2010;62(2):291-9.
103. [Nast A](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nast%20A%22%5BAuthor%5D), [Kopp I](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kopp%20I%22%5BAuthor%5D), [Augustin M](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Augustin%20M%22%5BAuthor%5D), [Banditt KB](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Banditt%20KB%22%5BAuthor%5D), [Boehncke WH](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Boehncke%20WH%22%5BAuthor%5D), et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). [*Arch Dermatol Res.*](http://www.ncbi.nlm.nih.gov/pubmed?term=German%20evidence-based%20guidelines%20for%20the%20treatment%20of%20Psoriasis%20vulgaris%20(short%20version)%20##) 2007;299(3):111-38.
104. National Institute for Health and Clinical Excellence (NICE). *Psoriasis: assessment and management* *[CG153].* 24 October 2012. <https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf-35109629621701> [Accessed 20/08/2025].
105. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. Treatments for inverse psoriasis: a systematic review. *J Dermatolog Treat*. 2019;31(8):786-793.
106. Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: A systematic literature review on this hidden skin disease. *Acta Derm Venereol*. 2011;91(1):5-11.
107. Dattola A, Silvestri M, Bennardo L, et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. *Dermatol Ther*. 2018;31(6):e12728.
108. Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. *South Med J.* 2014;107(11):724‐7.
109. Zaouak A, Chabchoub I, Essid D, Ben Jennet S, Hammami H, Fenniche S. Genital Involvement in Bullous Fixed Drug Eruption. *Skinmed*. 2019;17(5):306–309.
110. Maatouk I, Moutran R, Fahed M, Helou J. A "sexually transmitted" fixed drug reaction. *Sex Transm Dis*. 2014;41(10):626‐627.
111. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. *Urol Oncol.* 2007;25(5):361–7.
112. Arya M, Li R, Pegler K, Sangar V, Kelly JD, Minhas S, et al. Long-term trends in incidence, survival, and mortality of primary penile cancer in England. *Cancer Causes Control.* 2013;24(12):2169–76.
113. Kirrander P, Sherif A, Friedrich B, Lambe M, Håkansson U; Steering Committee of the Swedish National Penile Cancer Register. Swedish National Penile Cancer Register: incidence, tumour characteristics, management, and survival. *BJU Int*. 2016;117(2):287-92.
114. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. *Am J Pathol*. 2001;159(4):1211–8.
115. Miralles-Guri C, Bruni L, Cubilla AL, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. *J Clin Pathol*. 2009;62(10):870–8.
116. Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. *Lancet Oncol*. 2019;20(1):145-158.
117. Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis, and prevention. *World J Urol.* 2009;27(2):141–50.
118. Paolino G, Panetta C, Cota C, Muscardin L, Donati P, Di Carlo A. Lichen sclerosus and the risk of malignant progression: a case series of 159 patients. *G Ital Dermatol Venereol.* 2013;148(6):673–8.
119. Mentrikoski MJ, Stelow EB, Culp S, Frierson HF Jr, Cathro HP. Histologic and immunohistochemical assessment of penile carcinomas in a North American population. *Am J Surg Pathol*. 2014;38(10):1340–8.
120. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer*. 2008;123(1):187–94.
121. Thuret R, Sun M, Budaus L, et al. A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. *Cancer Causes Control.* 2013;24(1):71-9.
122. Ulff- Møller CJ, Simonsen J, Frisch M. Marriage, cohabitation, and incidence trends of invasive penile squamous cell carcinoma in Denmark 1978-2010. *Int J Cancer*. 2013;133(5):1173-9.
123. Larke NL, Thomas SL, dos Santos Silva I, et al. Male circumcision and penile cancer: a systematic review and meta-analysis. *Cancer Causes Control.* 2011;22(8):1097-110.

## Wolbarst A. Circumcision and penile cancer. *The Lancet.* 1932;219:150-3.

1. Schoen EJ. The relationship between circumcision and cancer of the penis. *CA Cancer J Clin*. 1991;41(5):306-9.
2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs- Part A: renal, penile, and testicular tumours. *Eur Urol*. 2016;70(1):93-105.
3. Hoekstra RJ, Trip EJ, Ten Kate FJ, Horenblas S, Lock MTW. Penile intraepithelial neoplasia: nomenclature, incidence and progression to malignancy in the Netherlands. *Int J Urol*. 2019;26(3):353-357.
4. Guimarães GC, Rocha RM, Zequi SC, et al. Penile cancer: epidemiology and treatment. *Curr Oncol Rep*. 2011;13(3):231–9.
5. Wieland U, Jurk S, Weissenborn S, Krieg T, Pfister H, Ritzkowsky A. Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. *J Invest Dermatol.* 2000 Sep;115(3):396-401.
6. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer:2014 update. *Eur Urol*. 2015;67(1):142-150.
7. Kravvas G, Ge L, Ng J, et al. The management of penile intraepithelial neoplasia (PeIN): clinical and histological features and treatment of 345 patients and a review of the literature. *J Dermatolog Treat*. 2020;33(2):1047-1062.
8. Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. *Eur Urol*. 2012;62(5):923-928.
9. Manjunath A, Brenton T, Wylie S, Corbishley CM, Watkin NA. Topical therapy for non-invasive penile cancer (Tis)-updated results and toxicity. *Transl Androl Urol.* 2017;6(5):803-8.
10. Chipollini J, Yan S, Ottenhof SR, Zhu Y, Draeger D, et al. Surgical management of penile carcinoma in situ: results from an international collaborative study and review of the literature. *BJU Int*. 2018;121(3):393–8.
11. Ilkay AK, Chodak GW, Vogelzang NJ, Gerber GS. Buschke-Löwenstein tumor: therapeutic options including systemic chemotherapy. *Urology*. 1993;42(5):599-602.
12. Kim SJ, Thompson AK, Zubair AS, et al. Surgical Treatment and Outcomes of Patients With Extramammary Paget Disease: A Cohort Study. *Dermatol Surg*. 2017;43(5):708-714.
13. Snast I, Sharon E, Kaftory R, et al. Nonsurgical Treatments for Extramammary Paget Disease: A Systematic Review and Meta-Analysis. *Dermatology*. 2020;236(6):493-499.
14. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. *Cochrane Database Syst Rev*. 2015;(5):CD008138.
15. Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. *Cochrane Database Syst Rev*. 2014;2014(5):CD009446.
16. Vena GA, Micali G, Santoianni P, Cassano N, Peruzzi E. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. *Int J Immunopath Pharmacol.* 2005;18(4):745-53.
17. Yale K, Awosika O, Rengifo-Pardo M, Ehrlich A. Genital Allergic Contact Dermatitis. *Dermatitis*. 2018;29(3):112-119.
18. Warshaw EM, Kimyon RS, Silverberg JI, et al. Evaluation of Patch Test Findings in Patients with Anogenital Dermatitis. *JAMA* *Dermatol.* 2019;156(1):85‐91.
19. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*. 2018;32(5):657‐82.
20. Abędź N, Pawliczak R. Efficacy, and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. *Postepy Dermatol Alergol*. 2019;36(6):752‐759.
21. Rubinstein I, Baum GL, Hiss Y. Sarcoidosis of the penis: report of a case. *J Urol.*1986 May;135(5):1016-7.
22. McLaughlin SS, Linquist AM, Burnett JW. Cutaneous sarcoidosis of the scrotum: a rare manifestation of systemic disease. *Acta Derm Venereol*. 2002; 82(3):216-7.
23. Pereira IB, Khan A. Sarcoidosis rare cutaneous manifestations: Vulval and perianal involvement. J Obstet Gynaecol. 2017;37(4):539-540.
24. May M, Gunia S, Siegsmund M, Kaufmann O, Helke C, Hoschke B, Wille AH. Testikulärer Keimzelltumor und Sarkoidose: Eine diagnostische Herausforderung [Coincidence of testicular germ cell tumor and sarcoidosis: A diagnostic challenge]. *Urologe A*. 2006 Sep;45(9):1176-80.
25. Singal A, Pandhi D, Kataria V, Arora VK. Tuberculosis of the glans penis: an important differential diagnosis of genital ulcer disease. Int J STD AIDS. 2017;28(14):1453-1455.
26. Arakeri SU, Sinkar P. An unusual gross appearance of vulval tuberculosis masquerading as tumor. Case Rep Obstet Gynecol. 2014;2014:815401.
27. Sinha RK, Mukherjee S, Kamal MR, Karmakar D. Tuberculosis of the glans penis healing with meatal stenosis. BMJ Case Rep. 2014;2014:bcr2013202155. Published 2014 Feb 5. doi:10.1136/bcr-2013-202155
28. Dederichs F, Iesalnieks I, Sladek M, et al. Genital Granulomatosis in Male and Female Patients With Crohn's Disease: Clinical Presentation and Treatment Outcomes. J Crohns Colitis. 2018;12(2):197-203. doi:10.1093/ecco-jcc/jjx131.
29. Phillips SS, Baird DB, Joshi VV, Rosenberg AJ, Janosko EO. Crohn's disease of the prepuce in a 12-year-old boy: a case report and review of the literature. Pediatr Pathol Lab Med. 1997;17(3):497-502.
30. Reinders MGHC, Kukutsch NA. Genital edema in childhood: harbinger of Crohn's disease? J Am Acad Dermatol. 2011;65(2):449-450. doi:10.1016/j.jaad.2010.02.037
31. Saadoun D, Wechsler B. Behçet's disease. *Orphanet J Rare Dis*. 2012;7:20.
32. Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. *Yonsei Med J*. 1997;38(6):423-427.
33. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. *Int J Dermatol*. 2003;42(5):346-351.
34. Ghate JV, Jorizzo JL. Behçet's disease and complex aphthosis. *J Am Acad Dermatol*. 1999;40(1):1-18;quiz 19-20.
35. Bandow GD. Diagnosis and management of vulvar ulcers. *Dermatol Clin*. 2010;28(4):753-63.
36. Alpsoy E, Zouboulis CC, Ehrlich G. Mucocutaneous lesions of Behcet’s disease. *Yonsei Med J*. 2007;48(4):573–85.
37. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. *Lancet*. 1990;335(8697):1078-1080.
38. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. 2014;28(3):338-347.
39. Kokturk A. Clinical and Pathological Manifestations with Differential Diagnosis in Behçet's Disease. *Patholog Res Int*. 2012;2012:690390.
40. Ucar-Comlekoglu D, Fox A, Sen HN. Gender Differences in Behçet's Disease Associated Uveitis. *J Ophthalmol*. 2014;2014:820710.
41. Behçet’s UK. <https://behcetsuk.org/national-behcets-centres-of-excellence/> [Accessed 20/08/2025].
42. Hatemi G, Christensen R, Bang D*, et al.* 2018Update of the EULAR recommendations for the management of Behçet’s syndrome. *Ann Rheum Dis.* 2018;77(6):808-818.

**Editorial independence**

This guideline was commissioned, edited, and endorsed by the BASHH CEG without funding being sought or obtained.

**Conflict of interest**

All members of the guideline writing committee completed the BASHH conflict of interest declaration form at the time the guideline’s final draft was submitted to the CEG. No authors have any conflicts of interest to declare.

**Membership of the Clinical Effectiveness Group**

* Current membership of the BASHH Clinical effectiveness group is available at <https://www.bashh.org/guidelines>